(Amherst, NH) – Interest in nasal sprays for systemic drug delivery has increased dramatically in the last five years, driven by the need to develop new alternatives to oral delivery for protein and peptide-based drugs, and the belief that intranasal drug delivery may lead to greater drug efficacy, speed of action, safety, and patient compliance. Systemic intranasal drug delivery leverages the patient-friendly and favorable pharmacodynamics and pharmacoeconomics of intranasal administration to deliver drugs systemically. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.

As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization.

There are currently more than two-dozen companies actively pursuing intranasal drug delivery products. These companies believe the advantages of nasal drug delivery provide significant market opportunities, particularly against oral and injectable therapy. Systemic nasal sprays will grow at the expense of the predominant drug delivery methods which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.
Detailed analysis of systemic intranasal drug products, therapeutic sectors, and participants is included in a comprehensive report. The report – Systemic Nasal Sprays: Products, Players, Markets and Forecasts - documents and analyzes the results of a recent survey conducted by Greystone Research Associates.

More information is available at www.greystoneassociates.org



Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.